title: [Drug regulatory agency comments on the editorial about the new influenza drugs].
authors.forename: O
authors.initials: O
authors.lastname: Tokola
authors.forename: M
authors.initials: M
authors.lastname: Pasanen
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005387:Finland; D006146:Guanidines; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000517:prevention & control; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D011714:Pyrans; D012794:Sialic Acids / Q000627:therapeutic use*; D053243:Zanamivir
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D009439:Neuraminidase; D053243:Zanamivir
vernacular_title: Lääkelaitoksen kannanotto pääkirjoitukseen uusista influenssalääkkeistä.